{"component": "definition", "props": {"groups": [{"size": 69, "snippet_links": [{"key": "section-21", "type": "clause", "offset": [29, 40]}], "snippet": "has the meaning set forth in Section 2.1.", "samples": [{"hash": "hLWQhrlGWH0", "uri": "/contracts/hLWQhrlGWH0#collaboration", "label": "Collaboration and License Agreement (Carisma Therapeutics Inc.)", "score": 36.6577682495, "published": true}, {"hash": "4kwyDBGwB7f", "uri": "/contracts/4kwyDBGwB7f#collaboration", "label": "Master Collaboration and License Agreement (Immatics N.V.)", "score": 35.2176589966, "published": true}, {"hash": "hbE3d1JDuTT", "uri": "/contracts/hbE3d1JDuTT#collaboration", "label": "Collaboration Agreement (Biogen Inc.)", "score": 34.1225204468, "published": true}], "hash": "12e4a5d0f1b5fcf1dbf3e958ec252605", "id": 1}, {"size": 65, "snippet_links": [{"key": "health-care-providers", "type": "definition", "offset": [58, 79]}], "snippet": "means the communication and decision-making process among health care providers", "samples": [{"hash": "1E5SwS31sWy", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?211+ful+HB1953+pdf", "label": "legacylis.virginia.gov", "score": 18.0841140747, "published": false}, {"hash": "5z4XrRgaOHJ", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?221+ful+HB145E+pdf", "label": "legacylis.virginia.gov", "score": 17.7651958466, "published": false}, {"hash": "fltRpDwLglp", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?212+ful+HB1747+pdf", "label": "legacylis.virginia.gov", "score": 17.7089920044, "published": false}], "hash": "042eff8ab42ee5e0ca021a94b7674793", "id": 2}, {"size": 58, "snippet_links": [], "snippet": "means a process involving 2 or more health", "samples": [{"hash": "eDMr3vnAFp5", "uri": "https://www.ilga.gov/legislation/104/HB/PDF/10400HB1887lv.pdf", "label": "www.ilga.gov", "score": 19.9775562286, "published": false}, {"hash": "f9vjXayaJtI", "uri": "https://www.ilga.gov/legislation/104/SB/PDF/10400SB1908.pdf", "label": "www.ilga.gov", "score": 19.9753303528, "published": false}, {"hash": "ftc2fxgZi", "uri": "https://www.ilga.gov/legislation/104/HB/PDF/10400HB1652.pdf", "label": "www.ilga.gov", "score": 19.8936901093, "published": false}], "hash": "0f5c5d6958af2d22063c85ee318f6970", "id": 3}, {"size": 56, "snippet_links": [{"key": "activities-of-the-parties", "type": "clause", "offset": [10, 35]}, {"key": "in-performance", "type": "clause", "offset": [48, 62]}, {"key": "the-relationship-between-the-parties", "type": "clause", "offset": [71, 107]}, {"key": "this-agreement", "type": "clause", "offset": [124, 138]}], "snippet": "means the activities of the Parties carried out in performance of, and the relationship between the Parties established by, this Agreement.", "samples": [{"hash": "aLhmsXYm4fv", "uri": "/contracts/aLhmsXYm4fv#collaboration", "label": "Collaboration and License Agreement (Cardiome Pharma Corp)", "score": 21.0, "published": true}, {"hash": "ggkOtB2tzKL", "uri": "/contracts/ggkOtB2tzKL#collaboration", "label": "Collaboration Agreement (Axys Pharmecueticals Inc)", "score": 18.0, "published": true}, {"hash": "g7uHA0zfflK", "uri": "/contracts/g7uHA0zfflK#collaboration", "label": "Collaboration, License and Supply Agreement (Atrix Laboratories Inc)", "score": 18.0, "published": true}], "hash": "e3fcff1a85305d0f9af083a4974770ce", "id": 4}, {"size": 50, "snippet_links": [{"key": "members-of", "type": "clause", "offset": [58, 68]}, {"key": "patient-care-team", "type": "definition", "offset": [71, 88]}, {"key": "related-to", "type": "clause", "offset": [89, 99]}, {"key": "data-and-information", "type": "definition", "offset": [170, 190]}, {"key": "development-of", "type": "clause", "offset": [304, 318]}, {"key": "an-appropriate", "type": "clause", "offset": [319, 333]}, {"key": "plan-of-care", "type": "definition", "offset": [334, 346]}, {"key": "health-care", "type": "clause", "offset": [382, 393]}, {"key": "additional-resources", "type": "definition", "offset": [444, 464]}], "snippet": "means the communication and decision-making process among members of a patient care team related to the treatment and care of a patient and includes (i) communication of data and information about the treatment and care of a patient, including exchange of clinical observations and assessments; and (ii) development of an appropriate plan of care, including decisions regarding the health care provided, accessing and assessment of appropriate additional resources or expertise, and arrangement of appropriate referrals, testing, or studies.", "samples": [{"hash": "3X5SDhVjs2A", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?161+ful+CHAP0495+pdf", "label": "legacylis.virginia.gov", "score": 17.7250404358, "published": false}, {"hash": "lC8p6b5DZd2", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?151+ful+CHAP0107+pdf", "label": "legacylis.virginia.gov", "score": 17.652885437, "published": false}, {"hash": "fNyqfdzhcI8", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?121+ful+CHAP0213+pdf", "label": "legacylis.virginia.gov", "score": 17.6208648682, "published": false}], "hash": "542610513d1d4721e85a5bc0e2f21a84", "id": 5}, {"size": 44, "snippet_links": [], "snippet": "or \"collaborating\" means the following:", "samples": [{"hash": "255S2E3TzHQ", "uri": "https://search-prod.lis.state.oh.us/api/v2/general_assembly_136/legislation/hb52/00_IN/pdf/", "label": "search-prod.lis.state.oh.us", "score": 20.2426681519, "published": false}, {"hash": "4M4KaYFEbUs", "uri": "https://search-prod.lis.state.oh.us/api/v2/general_assembly_134/legislation/hb496/00_IN/pdf/", "label": "search-prod.lis.state.oh.us", "score": 19.2194232941, "published": false}, {"hash": "beNnwvq6Fjc", "uri": "https://search-prod.lis.state.oh.us/api/v2/general_assembly_134/legislation/hb509/05_EN/pdf/", "label": "search-prod.lis.state.oh.us", "score": 19.1403770447, "published": false}], "hash": "8d3fc39a408856d4d0a69197c5340f11", "id": 6}, {"size": 44, "snippet_links": [{"key": "for-purposes-of", "type": "clause", "offset": [7, 22]}, {"key": "class-size", "type": "definition", "offset": [35, 45]}, {"key": "section-2", "type": "clause", "offset": [64, 73]}, {"key": "a-teacher", "type": "clause", "offset": [75, 84]}, {"key": "exceptional-children", "type": "clause", "offset": [88, 108]}, {"key": "children-with-disabilities", "type": "definition", "offset": [120, 146]}, {"key": "to-provide", "type": "definition", "offset": [172, 182]}, {"key": "specially-designed-instruction", "type": "definition", "offset": [183, 213]}, {"key": "related-services", "type": "clause", "offset": [218, 234]}], "snippet": "means, for purposes of determining class size in 707 KAR 1:350, Section 2, a teacher of exceptional children works with children with disabilities in the regular classroom to provide specially designed instruction and related services.", "samples": [{"hash": "2H5WYruUEu3", "uri": "https://core-docs.s3.us-east-1.amazonaws.com/documents/asset/uploaded_file/2869/LCPS/4910433/Letcher_County_Special_Education_Procedures_Revised_2022.docx", "label": "core-docs.s3.us-east-1.amazonaws.com", "score": 17.6858654022, "published": false}, {"hash": "hKsJUr2xKcM", "uri": "https://resources.finalsite.net/images/v1729268435/hartk12kyus/tu5rkm2jbvocnbezcdcj/HCSDSpEdProceduresboardapproved101724_1.pdf", "label": "resources.finalsite.net", "score": 17.5369625092, "published": false}, {"hash": "1grPW4WDmAT", "uri": "https://resources.finalsite.net/images/v1728485564/racelandk12kyus/mmlhxcauau4t3twj5vtb/specialeducationpolicyprocedures.pdf", "label": "resources.finalsite.net", "score": 17.4696083069, "published": false}], "hash": "dbfc2d4d5a4e36f9dc16225d78abdfa9", "id": 7}, {"size": 41, "snippet_links": [{"key": "activities-of-the-parties", "type": "clause", "offset": [10, 35]}, {"key": "manufacture-of-licensed-products", "type": "clause", "offset": [59, 91]}, {"key": "this-agreement", "type": "clause", "offset": [98, 112]}, {"key": "development-supply-agreement", "type": "clause", "offset": [124, 152]}], "snippet": "means the activities of the Parties in the Development and Manufacture of Licensed Products under this Agreement and/or the Development Supply Agreement.", "samples": [{"hash": "toyNMkJhal", "uri": "/contracts/toyNMkJhal#collaboration", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 34.1444206238, "published": true}, {"hash": "8wkFXVcAmCH", "uri": "/contracts/8wkFXVcAmCH#collaboration", "label": "Development and Marketing Agreement", "score": 27.0520191193, "published": true}, {"hash": "h4IzP3EHexR", "uri": "/contracts/h4IzP3EHexR#collaboration", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 24.5646820068, "published": true}], "hash": "1ebe11242c2f4949853a4ad501b5e907", "id": 8}, {"size": 35, "snippet_links": [{"key": "collaborative-research", "type": "definition", "offset": [10, 32]}, {"key": "commercialization-program", "type": "definition", "offset": [51, 76]}, {"key": "between-the-parties", "type": "clause", "offset": [77, 96]}, {"key": "contemplated-by-this-agreement", "type": "clause", "offset": [105, 135]}], "snippet": "means the collaborative research, development, and commercialization program between the Parties that is contemplated by this Agreement.", "samples": [{"hash": "hOAxEpZ87oE", "uri": "/contracts/hOAxEpZ87oE#collaboration", "label": "Collaboration Agreement (Exelixis Inc)", "score": 22.5879535675, "published": true}, {"hash": "kwJD9zWsUL2", "uri": "/contracts/kwJD9zWsUL2#collaboration", "label": "Collaboration Agreement (Facet Biotech Corp)", "score": 21.0, "published": true}, {"hash": "iufFmk0qVhC", "uri": "/contracts/iufFmk0qVhC#collaboration", "label": "Collaboration Agreement (PDL Biopharma, Inc.)", "score": 21.0, "published": true}], "hash": "284fb2440d0a4eee7ddf9d89aa978699", "id": 9}, {"size": 30, "snippet_links": [{"key": "members-of", "type": "clause", "offset": [58, 68]}], "snippet": "means the communication and decision-making process among members of a patient", "samples": [{"hash": "6Pw97NFhzcq", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?161+ful+HB581+pdf", "label": "legacylis.virginia.gov", "score": 18.4060497284, "published": false}, {"hash": "h3EApQm3qcS", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?161+ful+SB620+pdf", "label": "legacylis.virginia.gov", "score": 17.9707355499, "published": false}, {"hash": "1y0le4VZgZ8", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?161+ful+SB463S1+pdf", "label": "legacylis.virginia.gov", "score": 17.9707355499, "published": false}], "hash": "fb7d8d0de45e2bd2ffd01adb96a3e5cb", "id": 10}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIWY29sbGFib3JhdGlvbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Collaboration", "size": 1752, "snippet": "has the meaning set forth in Section 2.1.", "id": "collaboration", "examples": ["Once satisfied conditions and terms foreseen under the Granting Notice of Option and the Part B Stock Option Agreement, specifically the Term of <strong>Collaboration</strong>, on each Anniversary as from the date of Vesting of Part B Shares, the Participant will be entitled to have the Trust\u2019s Trustee release and transfer thereto Part B Shares, subject to the exercise of Part B Stock Option; on the understanding that such exercise is to occur only within terms foreseen under the Part B Shares Release Schedule.", "Subject to the rights and licenses granted expressly hereunder, as between the Parties, Vir Bio shall solely own and retain all right, title and interest in and to any and all <strong>Collaboration</strong> IP.", "Other than the Original <strong>Collaboration</strong> Agreement, there has not occurred nor has there existed any transaction or relationship between the SPV and any Affiliate thereof.", "For purposes of this Section, \u201cProtected <strong>Collaboration</strong> Assets\u201d means (i) SunHydrogen Background Intellectual Property, (ii) 2024 TCA IP; (iii) Foreground Intellectual Property, and (iii) SunHydrogen Confidential Information.", "Without limitation to Section 15.12, Licensee shall assign and hereby assigns, and shall cause all of its Affiliates, Sublicensees, Distribution Partners and subcontractors to assign, irrevocably, without reservation, all of their respective rights, title, and interest in and to the <strong>Collaboration</strong> IP to Vir Bio.", "Notwithstanding the foregoing, \u2587\u2587\u2587\u2587\u2587\u2019s shared portion of the Commercialization and Related Costs incurred in performing any Clinical Studies conducted after Regulatory Approval for In-Line Products in the <strong>Collaboration</strong> Territory shall be subject to an annual maximum of [*] during each [*] period following the Effective Date and until January 1, 2026 subject to an aggregate maximum of [*].", "If the execution of the Underwriting Agreement does not occur on or before [***], then, in each case, this Agreement shall automatically terminate without further action by either Party, neither Party shall have any further obligations hereunder except for those provisions that expressly survive termination, and, for clarity, the Original <strong>Collaboration</strong> Agreement and the Drag-Along Agreement shall remain in full force and effect.", "This Section does not prohibit CTF from using its general skills, experience, and know-how, provided CTF does not use or disclose Protected <strong>Collaboration</strong> Assets contrary to this Agreement.", "The disclosure or sharing of \u201cProtected <strong>Collaboration</strong> Assets\u201d under 7.J.", "For clarity, prior to the execution of the Original <strong>Collaboration</strong> Agreement, Pioneering Medicines [***]."], "related": [["collaboration-know-how", "Collaboration Know-How", "<strong>Collaboration</strong> Know-How"], ["research-program", "Research Program", "Research Program"], ["collaboration-technology", "Collaboration Technology", "<strong>Collaboration</strong> Technology"], ["research-program-term", "Research Program Term", "Research Program Term"], ["collaboration-activities", "Collaboration Activities", "<strong>Collaboration</strong> Activities"]], "related_snippets": [], "updated": "2026-02-25T05:25:33+00:00"}, "json": true, "cursor": ""}}